Cases of Lymphoma and Other Cancers Decreasing Among HIV Sufferers

According to a new study, cases of AIDS-related cancers have decreased among people suffering from HIV in the United States. However, the same study finds that other types of cancer are growing in this same group.

In particular, Kaposi’s sarcoma, non-Hodgkin’s lymphoma and invasive cervical cancer are used by the U.S. Centers for Disease Control and Prevention when attempting to figure out if a person with HIV has developed AIDS.

As per the results of this study, AIDS-defining cancers decreased from 34,000 cases between 1991 and 1995 to nearly 10,000 cases between 2001 and 2005. This notable decline has been attributed to the introduction of a highly active antiretroviral therapy in 1996, which in turn improves immune function all the while reducing the progression of AIDS.

Unfortunately, the study also found that the total number all other types of cancers in people with HIV tripled from 3,000 cases between 1991 and 1995 to nearly 10,000 cases between 2001 and 2005.

"Our study observed striking increases for a number of malignancies related to cancer risk factors that are known to be prevalent in this population, such as smoking and infection with cancer-causing viruses," study author Meredith S. Shiels, from the division of cancer epidemiology and genetics at the National Cancer Institute, said in a journal news release. "We also observed increases for nearly all other cancers, which is what one might expect for an aging population."

This study was published online on April 11 in the Journal of the National Cancer Institute.

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap